AMENDMENT

In the Claims:

Please cancel claims 1-10 without prejudice or disclaimer to presentation in a later application.

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1-10. (Canceled)

11. (Original) A method of inhibiting Factor XIa in a mammal by administration of a small organic compound with an IC_{50} for inhibiting Factor XIa of less than 120 nM.

12. (Original) The method of claim 11, wherein the small organic compound has an IC_{50} for inhibiting Factor XIa of less than 10 nM.

13. (Original) The method of claim 11, wherein the small organic compound has an IC_{50} for inhibiting Factor XIa of less than 6 nM.

14. (Original) The method of claim 11, wherein the small organic compound has an IC_{50} for inhibiting Factor XIa of less than 1 nM.

15. (Original) A method of inhibiting Factor XIa in a mammal by administration of a small organic compound having the formula (I):



(I)

wherein:

R_1 and R_2 are hydrogen;

R_3 is hydrogen or CH_3;

R_4 is selected from hydrogen, CH_3, $-CO_2R_7$, $-C(=O)NR_8R_9$, phenyl, benzyl, and phenylethyl, wherein R_7 is hydrogen, C_{1-6}alkyl, benzyl, or $-CH(OCOCH_3)CH_3$; and each R_4 group is optionally substituted with one to two R_{12};

Y is C(=O) or $-SO_2-$; wherein when Y is C(=O), then R_6 is C_{1-6}alkyl, aryl, heteroaryl, or $-NR_{10}R_{11}$, and when Y is $-SO_2-$, then R_6 is aryl or heteroaryl; and each R_6 group is optionally substituted with one to two R_{12};

R_8 and R_9 are individually selected from hydrogen and C_{1-6}alkyl, or R_8 and R_9 taken together form a five or six membered heterocyclo ring optionally substituted with one to two R_{12} and up to one R_{13};

R_{10} and R_{11} are individually selected from hydrogen, phenyl, or C_{1-6}alkyl optionally substituted with phenyl, or R_{10} and R_{11} taken together form a five or six membered heterocyclo ring optionally substituted with one to two R_{12} and up to one R_{13};

R_{12} is selected from hydrogen, halogen, trifluoromethyl, trifluoromethoxy, lower alkyl, amino, lower alkylamino, $-CO_2H$, $-CO_2$(lower alkyl), or a five or six membered saturated or unsaturated heterocyclo having up to two nitrogen heteroatoms;

R_{13} is selected from $-C(=O)(C_{1-6}$alkyl), $-CO_2(C_{1-6}$alkyl), $-C(=O)NH(C_{1-6}$alkyl), and five or six membered heterocyclo optionally substituted with one to two R_{14}; and

R_{14} is selected from hydrogen, phenyl, or C_{1-6}alkyl optionally substituted with phenyl;

or a progdrug carbamate thereof wherein at least one of R_1 and R_2 is COOR, wherein R is hydrogen, C_{1-6}alkyl, benzyl, or $CH(OCOCH_3)CH_3$, or a pharmaceutically-acceptable salt or hydrate of said compound or prodrug carbamate.

16. (Original) The method of claim 15, wherein the small organic compound has the formula (Ia):



(Ia)

wherein:

R_3 is hydrogen or CH_3;

R_4 is CH_3, CO_2H, $CO_2(C_{1-4}$alkyl),  ,  or  ;

Y is C(=O) or $-SO_2-$; wherein:

when Y is C(=O), then R_6 is methyl, ethyl propyl,

 ,  ,  ,  ,


, 
, or 
;

when Y is $-SO_2-$, then R_6 is selected from 
or 
; and

R_{12} is selected from hydrogen, lower alkyl, amino, lower alkylamino, $-CO_2H$, and $-CO_2$(lower alkyl); or a progdrug carbamate thereof wherein at least one of R_1 and R_2 is -COOR, wherein R is hydrogen, C_{1-6}alkyl, benzyl, or $-CH(OCOCH_3)CH_3$, or a pharmaceutically-acceptable salt or hydrate of said compound or prodrug carbamate; wherein the compound has an IC_{50} for inhibiting Factor XIa of less than 20 nM.

17. (Original) The method of claim 15, wherein the small organic compound has the formula (Ib),



(Ib)

wherein:

R_6 is selected from:


, 
, 
, or 
;

or a progdrug carbamate thereof wherein at least one of R_1 and R_2 is -COOR, wherein R_{12} is defined as above; R is hydrogen, C_{1-6}alkyl, benzyl, or $-CH(OCOCH_3)CH_3$, or a

pharmaceutically-acceptable salt or hydrate of said compound or prodrug carbamate; wherein the compound has an IC_{50} for inhibiting Factor XIa of less than 3 nM.